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Abstract
Background: Unexpected clinical deterioration before 34 weeks gestation is an undesired course in early-onset
pre-eclampsia. To safely prolong preterm gestation, accurate and timely prediction of complications is required.
Method: Women with confirmed early onset pre-eclampsia were recruited from 53 maternity units in the UK to a
large prospective cohort study (PREP-946) for development of prognostic models for the overall risk of experiencing
a complication using logistic regression (PREP-L), and for predicting the time to adverse maternal outcome using a
survival model (PREP-S). External validation of the models were carried out in a multinational cohort (PIERS-634) and
another cohort from the Netherlands (PETRA-216). Main outcome measures were C-statistics to summarise
discrimination of the models and calibration plots and calibration slopes.
Results: A total of 169 mothers (18%) in the PREP dataset had adverse outcomes by 48 hours, and 633 (67%) by
discharge. The C-statistics of the models for predicting complications by 48 hours and by discharge were 0.84
(95% CI, 0.81–0.87; PREP-S) and 0.82 (0.80–0.84; PREP-L), respectively. The PREP-S model included maternal age,
gestation, medical history, systolic blood pressure, deep tendon reflexes, urine protein creatinine ratio, platelets,
serum alanine amino transaminase, urea, creatinine, oxygen saturation and treatment with antihypertensives or
magnesium sulfate. The PREP-L model included the above except deep tendon reflexes, serum alanine amino
transaminase and creatinine. On validation in the external PIERS dataset, the reduced PREP-S model showed
reasonable calibration (slope 0.80) and discrimination (C-statistic 0.75) for predicting adverse outcome by 48 hours.
Reduced PREP-L model showed excellent calibration (slope: 0.93 PIERS, 0.90 PETRA) and discrimination (0.81 PIERS,
0.75 PETRA) for predicting risk by discharge in the two external datasets.
Conclusions: PREP models can be used to obtain predictions of adverse maternal outcome risk, including early
preterm delivery, by 48 hours (PREP-S) and by discharge (PREP-L), in women with early onset pre-eclampsia in the
context of current care. They have a potential role in triaging high-risk mothers who may need transfer to tertiary
units for intensive maternal and neonatal care.
Trial registration: ISRCTN40384046, retrospectively registered.
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Background
Early-onset pre-eclampsia presents with hypertension
and proteinuria before 34 weeks’ gestation, and contrib-
utes disproportionately to pregnancy complications
compared to late-onset disease [1–4]. Complications ne-
cessitate intensive care in a third of women, who are at
risk of unexpected clinical deterioration [5, 6]. The only
known cure for the condition is delivery of the baby [7],
which often occurs at extreme preterm gestation, and re-
quires immediate neonatal intensive care.
A diagnosis of early onset pre-eclampsia with impending
complications, including iatrogenic preterm delivery be-
fore 34 weeks, often triggers transfer to a tertiary unit with
intensive care facilities for the mother and the preterm in-
fant. Given the paucity of neonatal intensive care beds and
high-dependency space for mothers in tertiary centres [8]
and the prolonged time and significant resources required
to facilitate the process [9, 10], an accurate estimation of
risk at various time points after diagnosis of early onset
pre-eclampsia is needed to prioritise and plan care. Infor-
mation on the mother’s overall risk status will determine
the intensity of monitoring in pregnancy.
Existing models on pre-eclampsia have not been de-
signed specifically to predict complications in early-onset
disease and do not have a sufficient sample size to ro-
bustly predict risks at various time points [1–4] due to the
small numbers of events per variable [3, 4, 11]. The ad-
verse outcomes predicted by the models do not include
risk of preterm delivery, an important component that in-
fluences decisions regarding in utero transfer [4]. Further-
more, the models do not take into account the effect of
treatment (including early delivery), which may influence
the choice of predictors and performance of models [12].
We developed multivariable prognostic models for
providing individual risks of adverse maternal outcomes,
including delivery of preterm infant before 34 weeks, in
women with early-onset pre-eclampsia in the UK, by
48 hours and by discharge. We externally validated these
in various independent datasets across the world [4, 11].
Methods
We conducted the study using a prospective protocol [13]
and reported in line with the TRIPOD (Transparent
Reporting of a multivariable prediction model for Individ-
ual Prognosis Or Diagnosis) recommendations [14–16]. A
panel of experts provided additional methodological input
on the development of prediction models [17]. The
National Research Ethics Service Committee (West
Midlands, UK) provided approval (11/WM/0248.)
Population
We approached potentially eligible mothers from 53 ob-
stetric units within secondary and tertiary care hospitals
in the UK. Information about the study was provided
when women attended the hospital for obstetric care.
We recruited consecutive women with suspected or con-
firmed pre-eclampsia before 34 weeks’ gestation from
December 2011 to April 2014. Women with confirmed
early-onset pre-eclampsia contributed to model develop-
ment (Additional file 1: Table S1). Women were ex-
cluded from the study if the outcome of interest had
occurred prior to the assessment of predictors, there
was insufficient time to obtain informed consent or
there was a lack of translators for non-English speaking
mothers. All women in the study were managed accord-
ing to National Institute for Health and Care Excellence
guidelines on Hypertension in Pregnancy [18].
Predictors
An initial list of 33 candidate predictors was identified
from published systematic reviews [19–24] and primary
studies [4, 25–30], and subsequently (before any data ana-
lysis) reduced to 22 after prioritising their importance by a
Delphi consensus among experts [22]. Candidate predic-
tors included maternal characteristics, relevant medical
history, symptoms, signs, investigations and interventions
that have the potential to modify the probability of out-
come (Table 1). In cases of multiple collected values for
the same predictor, we chose the worst value within the
first 24 hours. We also considered predictors for fetal out-
comes shown in Additional file 1: Table S2.
Outcomes
An independent panel of experts ranked the outcomes
for their importance to clinical practice [17]. Based on
the PIERS study, the components of the outcome were
identified by a Delphic consensus [3]. We defined the
primary outcome as maternal complication that included
maternal death, neurological, hepatic, cardiorespiratory,
renal or haematological complications, or delivery before
34 weeks (Additional file 1: Table S3a). The panel agreed
that delivery before 34 weeks is often offered for medical
reasons to avoid complications as per the national guide-
lines; thus, excluding this as an adverse outcome would
underestimate the true incidence of adverse outcomes and
lead to prognostic models that yield too low risk predic-
tions of actually developing an adverse outcome [17].
Hence, deliveries before 34 weeks’ gestation were added as
a component of the primary outcome before data analysis.
The secondary outcomes included composite perinatal
outcomes by discharge, which were also developed by Del-
phi consensus (Additional file 1: Table S3b) [3].
Sample size
Based on systematic reviews on accuracy of tests in pre-
dicting complications in women with pre-eclampsia [3,
19, 23, 24], we expected 20% of women with early-onset
pre-eclampsia to develop adverse maternal outcome at
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any time point, and about 10 events were required for
each candidate predictor to reduce model overfitting is-
sues [31]. We revised our initial sample size of 500
women, to continue recruitment until 100 adverse mater-
nal events were reached. Prior to analysis, discussions with
the independent Steering Committee resulted in extension
of the primary outcome to also include delivery before
34 weeks’ gestation [17] (Additional file 1: Table S4).
Datasets for external validation
We externally validated the developed PREP models in
two independent datasets, namely the PIERS (Pre-
eclampsia Integrated Estimate of RiSk) study [4], a
prospective cohort on prediction of adverse maternal
outcomes in women with any-onset pre-eclampsia (634
Table 1 Details of candidate predictors of women in the PREP
study and the proportion with missing values
Candidate predictor Women with early
onset pre-eclampsia
n = 954
Mean (SD) or n (%)
Number of women
with missing data
n (%)
Maternal characteristics
Maternal age (years),
mean (SD)
30.2 (6.1) 2 (0.2%)
Gestational age at
diagnosis (weeks),
mean (SD)
30.5 (2.9) –
Number of fetuses in
pregnancya
Singleton 866 (91%)
Twins 83 (9%) –
Triplets 5 (1%)
Parity –
0 551 (58%)
1 207 (22%)
2 109 (11%)
3 55 (6%)
4 20 (2%)
5 – 9 12 (1%)
History
Medical historyb 1 (0.1%)
None 601 (63%)
At least one condition 251 (26%)
Two or more conditions 101 (11%)
Chronic hypertension 139 (15%) 10 (1.0%)
Renal disease 30 (3%) 10 (1.0%)
Previous history of pre-
eclampsia
169 (43%) 558b
Autoimmune disease 18 (2%) 32 (3.4%)
Diabetes mellitus 109 (11%) 6 (0.6%)
Symptoms
Symptoms of headache
and/or visual disturbance
382 (41%) 28 (2.9%)
Symptoms of epigastric
pain, nausea and/or vomiting
202 (22%) 47 (4.9%)
Symptoms of chest pain
and/or breathlessness
60 (7%) 126 (13.2%)
Bedside examination and tests
Systolic blood pressure
(mmHg), mean (SD)
159 (19) 5 (0.5%)
Diastolic blood pressure
(mmHg), mean (SD)
99 (12) 5 (0.5%)
Clonus 95 (17%) 403 (42.2%)
Exaggerated tendon reflexes 147 (24%) 353 (37%)
Oxygen saturation by pulse
oximetry (%), mean (SD)
98 (2) 521 (54.6%)
Table 1 Details of candidate predictors of women in the PREP
study and the proportion with missing values (Continued)
Oxygen saturation: abnormal
(< 94%)
4 (1%) 521 (54.6%)
Urine dipstick
None/Trace 39 (4%)
1+ 170 (18%)
2+ 314 (34%) 19 (2%)
3+ 306 (33%)
≥ 4 106 (11%)
Laboratory tests
Haemoglobin (g/L), mean
(SD)
11.9 (1.3) 37 (3.9%)
Platelet count (× 109/L),
mean (SD)
226 (78) 41 (4.3%)
Alanine transaminase (U/L),
mean (SD)
31.0 (71.0) 75 (7.9%)
Serum uric acid (μmol/L),
mean (SD)
0.6 (2.7) 165 (17.3%)
Serum urea (mmol/L), mean
(SD)
4.6 (4.4) 70 (7.3%)
Serum creatinine (μmol/L),
mean (SD)
61.0 (17.8) 38 (4%)
Urine PCR (mg/mmol), mean
(SD)
273 (492) 109 (11.4%)
Treatment provided
Any anti-hypertensive
therapyc
753 (79%) 6 (0.6%)
Oral anti-hypertensive
therapy
734 (77%) 6 (0.6%)
Parenteral anti-hypertensive
therapy
111 (12%) 6 (0.6%)
Parenteral magnesium
sulfated
144 (15%) 6 (0.6%)
aNumber of pregnancies
bAll missing values are for nulliparous women where previous occurrence of
pre-eclampsia is not applicable
cOn-going at diagnosis or introduced within 1 day of diagnosis
dAdministered any time before diagnosis or within 24 h of diagnosis
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women recruited in Canada, New Zealand, Australia
and the UK), and the PETRA (Pre-Eclampsia TRial
Amsterdam) study, a randomised trial on effectiveness
of plasma expansion in the management of early-onset
hypertensive disease in pregnancy (216 women) [11].
Data analysis
Model development
We developed two prediction models – a survival model
(PREP-S) censored at 34 completed weeks’ gestation to
predict the risk over time at daily intervals from diagnosis
of early onset pre-eclampsia, and a logistic regression
model (PREP-L) to predict the overall risk of maternal
complications by postnatal discharge. We evaluated the
performance of the models in terms of calibration and dis-
crimination. Calibration assesses if the predicted risks
agree with the observed risks. We reported this graphically
using calibration plots and estimated the calibration slope
(with 95% confidence intervals) across the spectrum of
predicted risks for included women; a calibration slope of
1 is desired. In addition to calibration slopes for both
models, we calculated the ratio of observed to predicted
probability of outcome for the PREP-S model in various
risk groups at 48 hours, 1 week and overall. Discrimin-
ation indicates how well the model separates mothers
without complications from those with complications, and
was quantified using Harrell’s C-statistic for the PREP-S
model, and the generic C-statistic for the PREP-L model
with 95% confidence intervals (CI). A C-statistic of 0.5 in-
dicates no discrimination beyond chance, whereas a C-
statistic of 1 indicates perfect discrimination.
We used the Royston–Parmar approach for the survival
analysis (PREP-S) [32–34] to model the cumulative baseline
hazard scale using restricted cubic splines [35]. The num-
bers of knots in the spline function were chosen based on
visual inspection and goodness-of-fit statistics [32–34].
During development of both models, we used the ICE
package in Stata with five imputations to deal with miss-
ing predictor values under a missing at random assump-
tion [35]. The estimates across imputed datasets were
combined using Rubin’s rules to produce final parameter
estimates for the model [36]. No outcomes were im-
puted. Sensitivity analysis examined the impact of in-
creasing the number of imputed datasets to 40.
For each PREP-S and PREP-L models separately, we
started with the full model (including all candidate predic-
tors) and used backwards selection to identify predictors to
include at P < 0.15 of the log likelihood ratio test. We
forced gestational age and maternal age at diagnosis into
the models to ensure clinical acceptability of the final
model. We evaluated non-linear trends of the continuous
predictors using multivariable fractional polynomials, with
P < 0.01 (for the change in model fit) used to justify the
non-linear trends. We reported the model performance at
48 hours, 1 week and overall. A sensitivity analysis was con-
ducted by adding oral and parenteral anti-hypertensives
separately into the final models to check if model fit was
improved by using a likelihood ratio test with P < 0.15. We
checked the final PREP-S model for time dependent effects
(non-proportional hazards) of included predictors.
Internal validation and adjustment for over-optimism
We internally validated the performance of our models. We
estimated their apparent (i.e. before adjustment for model
overfitting) calibration and discrimination, by averaging
across performance across imputed datasets. We used non-
parametric bootstrapping to estimate over-optimism in per-
formance, where in each of 100 bootstrap samples we re-
peated the entire modelling process (including predictor
selection) and compared apparent model performance (in
bootstrap sample) with performance in the original sample.
The average optimism across all bootstrap samples was
then used to calculate, for our developed models, their
optimism-adjusted C-statistics and optimism-adjusted cali-
bration slopes. Based on the latter, uniform shrinkage fac-
tors were applied to all the predictor effects in the final
developed models to account for the over-optimism identi-
fied. The choice of imputed dataset to obtain bootstrap
samples from made little difference to the optimism
estimates.
External validation
For assessment of model transportability, the final
optimism-adjusted models were externally validated in the
PIERS and PETRA datasets. However, as some predictors
in the final models were not available in the external data-
sets, we developed a reduced version of our final models.
That is, we re-estimated the available predictor effects and
intercept terms within the models using the development
data, and adjusted for optimism according to the method
described above. These reduced PREP models were then
validated in the PIERS and PETRA population.
To examine calibration graphically, women were
grouped into four risk categories, namely low (<15th
centile), intermediate (15–50th), high (> 50–85th) and
very high (> 85th) in the PREP-S model, and into tenths
of predicted risk (defined by deciles) in the PREP-L
model. If necessary, we examined whether recalibration
of the intercepts of the developed models improved their
performance in the validation sets.
Prediction of secondary (adverse perinatal) outcomes
A logistic regression model was used to predict the risk of
adverse perinatal outcomes, as for the maternal outcomes.
In addition to the maternal predictors, we evaluated cardi-
otocography and uterine artery Doppler. Pregnancy was
the unit of analysis and non-linear terms were not
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considered. A similar variable selection process on the full
list of maternal and fetal candidate predictors was done.
All analyses were carried out using Stata version 12.0 [35].
Results
We screened 3302 pregnant women, of whom 1101 were
recruited to the study. There were 954 women with con-
firmed early-onset pre-eclampsia. We included 946
women with complete outcome data in the final predic-
tion models (Fig. 1).
Characteristics of women in the PREP study
Over 90% (866/954) of women with early-onset pre-
eclampsia had new onset disease. More than half of all
women were nulliparous (551/954, 58%) and the mean
gestational age of diagnosis was 30.5 (SD 2.9) weeks. More
than three-quarters of women were on anti-hypertensives
at baseline (753/948, 79%). Of the 15% of mothers who re-
ceived magnesium sulfate at baseline in the PREP study,
the rationale was documented as severe pre-eclampsia in
72% (104/144), and not reported in the rest (Table 1).
Outcomes
About a fifth of mothers diagnosed with the condition suf-
fered a complication (169/946, 18%) by 48 hours after diag-
nosis of early onset pre-eclampsia, and two-thirds (633/946,
66.9%) by postnatal discharge. The most frequent outcome
was early preterm delivery before 34 weeks gestation (580/
946, 61.3%), followed by postpartum haemorrhage (74/946,
7.8%) (Additional file 1: Table S5a). Three-quarters of all
neonates (702/945, 74%) had suffered at least one complica-
tion by discharge, with admission to the neonatal intensive
care unit being the most common outcome in 72% (681/
945) (Additional file 1: Table S5b).
Model development
PREP-S model: risks at various time points
The apparent and optimism-adjusted Harrell’s C-statistic
of the developed PREP-S model were 0.77 (95% CI,
0.75–0.79) and 0.75 (95% CI, 0.73–0.78), respectively.
The optimism-adjusted C-statistic of the model by
48 hours and 1 week was 0.84 (95% CI, 0.81–0.87) and
0.79 (95% CI, 0.76–0.81), respectively. The final predic-
tors included in the PREP-S model are listed in Box 1.
Figure 2 shows the model-based mean survival curves
for these prognostic groups compared to their observed
Kaplan–Meier survival curves up to 1 month after diag-
nosis. Overall, there was excellent apparent agreement,
both at 48 hours and by 1 week after delivery, across all
risk categories. In the highest risk group (> 90th centile),
81% of mothers experienced the adverse outcome by
48 hours after diagnosis and 96% by 1 week. In the low-
est risk group (≤ 10th centile), adverse maternal out-
come rate was 2% by 48 hours after diagnosis and 7% by
1 week. The bootstrap approach showed an optimism of
0.14 in calibration slope, and thus we reduced the pre-
dictor effect estimates within the final model by the uni-
form shrinkage factor of 0.86 (Box 1). Sensitivity analysis
Fig. 1 Flow of women recruited in the PREP study for development
of prediction model(s) for adverse maternal outcomes
Box 1: Full PREP prognostic models to calculate the risk of adverse
maternal outcomes in women with early onset pre-eclampsia
a. Risk at various time points from diagnosis until 34 weeks’
gestation using the survival model (PREP-S)
S(t) = S0 (t)
§ ^exp ((β1*X1 +⋯ + βn*Xn))
S(t) = S0(t)^exp(– 0.031*maternal age + 1.514*((Log(GA at diagnosis/10))
–2
– 0.8345136) + 5.707*((Log(GA at diagnosis/10))–2* ln(log(GA at
diagnosis/10)) – 0.0652155) + 0.122 (exaggerated tendon reflexes)
– 0.169 (one pre-existing medical condition) – 0.384 (two or more
pre-existing medical conditions) + 0.016*systolic blood pressure + 0.797
(oxygen saturation < 94% on air) – 0.002*platelet count + 0.126*log(alanine
amino transferase) + 0.605*log(serum urea)2 – 0.144*log(serum urea)3
+ 0.265*log(serum creatinine) + 0.080*log(protein creatinine ratio) + 0.176
(baseline treatment with any antihypertensive) + 1.066 (baseline treatment
with magnesium sulfate))
§ S0 (t) – baseline survival adjusted for optimism at time t
S0(48 hrs) = 0.99142, S0(72 hrs) = 0.98542, S0(1 week) = 0.96492,
S0(1 month) = 0.87377
b. Overall risk by postnatal discharge using the logistic model (PREP-L)
Probability (maternal adverse outcome) = exp(X)/(1 + exp(X)),
Where X = – 1.507– 0.020*maternal age + 12.052*(log (gestational age))3
– 39.90241) – 7.930*((log (gestational age))3*log(log (gestational age)
– 49.08188) – 0.330 (if one pre-existing medical condition) – 0.579 (if two
or more pre-existing medical conditions) + 0.146*log (urine protein creatinine
ratio) – 0.951*(log (serum urea)–1) – 0.004*platelet count + 0.024*systolic
blood pressure + 0.409 (baseline treatment with antihypertensive) + 1.252
(baseline treatment with magnesium sulfate)
Predictor value is 1 when present and 0 when absent
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(e.g. increasing the number of imputations for missing
data from 5 to 40) identified no important changes in
the developed model or its C-statistic.
PREP-L model: risk by postnatal discharge
The apparent C-statistic for the PREP-L model was 0.84
(95% CI, 0.82–0.87) and following bootstrap adjustment
for optimism it was 0.82 (95% CI, 0.80–0.84) (Table 2).
The final predictors included in the logistic PREP-L model
are listed in Box 1. The apparent calibration plot in Fig. 2
shows mostly good agreement between predicted versus
observed risks. We identified an optimism of 0.14 for the
calibration slope, and thus reduced the predictor effect es-
timates within the final developed model by the uniform
shrinkage factor of 0.86 (Box 1). Sensitivity analyses did
not identify any important changes.
External validation of PREP models
In the external datasets, data were available for 636
(PIERS study) and 216 women (PETRA study) with early-
onset pre-eclampsia (Additional file 1: Table S6). The re-
duced version of the PREP-S (without serum urea and
deep tendon reflex) and PREP-L (without serum urea)
models were evaluated in the PIERS and PETRA cohorts.
PREP-S model performance in external datasets
Calibration The calibration slopes at 48 hours, 1 week and
overall were 0.80 (95% CI, 0.62–0.99), 0.75 (95% CI, 0.61–
0.89) and 0.67 (95% CI, 0.56–0.79), respectively, on valid-
ation in the PIERS external dataset (Table 2). There was
good calibration between observed and predicted probability
of survival without complications in the low- (91% vs. 95%)
and intermediate-risk (88% vs. 89%) groups at 48 hours, but
with under prediction of survival in the high- (90% vs. 70%)
and very high-risk (46% vs. 28%) groups (Table 3).
Discrimination The C-statistic of the reduced PREP-S
model was 0.75 (95% CI, 0.69–0.81) at 48 hours, 0.72
(95% CI, 0.68–0.76) at 1 week after diagnosis and
0.71 (95% CI, 0.67–0.75) overall. The performance of
the PREP-S model could not be evaluated in the
PETRA dataset due to non-availability of data on
time to event.
PREP-L model performance in external datasets
The reduced PREP-L model showed excellent agreement
between predicted and observed risks, with a calibration
slope of 0.93 (95% CI, 0.72–1.13). The C-statistic of 0.81
Fig. 2 Apparent performance and calibration in the external cohorts of the PREP models for predicting adverse maternal outcomes in early onset pre-eclampsia
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(95% CI, 0.77–0.85) in the PIERS dataset (Table 2 and Fig. 2)
was similar to that observed in the development data, and
the reduced model separates women into low-, intermedi-
ate-, high- and very high-risk groups in the PIERS cohort
similar to the PREP data. Recalibration of the intercept
term to the PIERS data did not improve the calibration
slope. In the PETRA dataset, the reduced model had good
calibration (0.90; 95% CI, 0.48–1.32), though with slight
over-prediction in most tenths (Fig. 2), and a slightly lower
C-statistic than before (0.75; 95% CI, 0.64–0.86).
Risk of adverse perinatal outcomes
An increase in the gestational age at diagnosis of pre-
eclampsia and any pre-existing medical history were as-
sociated with a reduction in the odds of perinatal
complications (OR, 0.91; 95% CI, 0.39–0.99 and OR,
0.65; 95% CI, 0.44–0.98, respectively). Raised urine pro-
tein:creatinine ratio (OR, 1.29; 95% CI, 1.11–1.50),
serum urea (OR, 1.72; 95% CI, 1.07–2.76), management
with anti-hypertensives (OR, 1.56; 95% CI, 1.04–2.37),
treatment with magnesium sulfate (OR, 2.40; 95% CI,
1.04–5.57), abnormal uterine artery Doppler (OR, 1.94;
95% CI, 1.08–3.51), and when the expected fetal weight
was less than 10th centile by ultrasound (OR, 2.54; 95%
CI, 1.46–4.40) were all associated with an increase in the
odds of complications (Additional file 1: Table S2).
Discussion
We have developed and validated models to predict ma-
ternal complications, including preterm delivery, in
Table 2 Performance of the PREP-S (risk at various time points) and PREP-L (overall risk by discharge) models in the derivation
cohort and the external validation datasets for prediction of complications in women with early onset pre-eclampsia
Model performance Development cohort External cohorts
PREP PIERS PETRA
PREP-S model N = 946 N = 339
C-statistic (95% CI) –
At 48 hours 0.84 (0.81–0.87)b 0.75 (0.69–0.81)a
At 1 week 0.79 (0.76–0.81)b 0.72 (0.68–0.76)a
Overall 0.75 (0.73–0.78)b,c 0.71 (0.67–0.75)a
Calibration slope (95% CI) –
At 48 hours 1 0.80 (0.62–0.99)
At 1 week 1 0.75 (0.61–0.89)
Overall 1 0.67 (0.56–0.79)
PREP-L model N = 946 N = 437 N = 211
C-statistic (95% CI) 0.82 (0.80, 0.84)b,d 0.81 (0.77–0.85)a 0.75 (0.64–0.86)a
Calibration slope (95% CI) 1 0.93 (0.72–1.13) 0.90 (0.48–1.32)
CI confidence interval; N number of women analysed; PREP PRediction of complications in Early-onset Pre-eclampsia study; PIERS Pre-eclampsia Integrated Estimate
of RiSk study; PETRA Pre-Eclampsia TRial Amsterdam study
aApparent C-statistic
bOptimism adjusted C-statistic
cOverall apparent C-statistic 0.77 (95% CI 0.75, 0.79)
dApparent C-statistic 0.84 (95% CI, 0.82–0.87)
Table 3 Comparison of observed and predicted probability of survival using PREP-S model at 48 hours and by 1 week after diagno-
sis of early onset pre-eclampsia in external datasets
Risk stratification
(No. of women)
Time External validation in PIERS cohort
Observed survival probability
S tð Þ 
Predicted survival probability
(Ŝ(t))
Ratio S tð Þ = S^ tð Þ 
≤ 15th
(n = 59)
48 hours 0.91 0.95 0.96
1 week 0.81 0.79 1.0
> 15th–50th
(n = 70)
48 hours 0.88 0.89 1.0
1 week 0.62 0.60 1.0
> 50th –85th
(n = 123)
48 hours 0.90 0.70 1.3
1 week 0.40 0.23 1.7
> 85th
(n = 87)
48 hours 0.46 0.28 1.6
1 week 0.14 0.02 7.0
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women with early onset pre-eclampsia. The models are
based on routine tests, which are performed in clinical
practice on suspicion or confirmation of pre-eclampsia.
The PREP-S model can be used at the point of care to
predict the risks of complications at various time points,
including 48 hours, whereas the PREP-L can be used to
provide overall risk by postnatal discharge. The apparent
performances of the models show good discrimination
at 48 hours, and by discharge. In terms of discrimination
performance in external datasets, the C-statistic esti-
mates for reduced models were similar to those observed
in the PREP data for all models. For calibration perform-
ance in external datasets, the reduced PREP-L and
PREP-S models had some over-prediction with calibra-
tion slopes less than 1, but miscalibration was only slight
for PREP-L by discharge and PREP-S by 48 hours.
Strengths and limitations
We developed the PREP models by using a large, well-
defined and prospectively collected cohort of mothers
from several centres in the UK. We clearly defined the
predictors, and only used values within 24 hours of diag-
nosis of early onset pre-eclampsia, to allow application
of the model at the point of diagnosis. The final models
included clinically relevant predictors used in practice to
assess disease severity, such as blood pressure, thereby
providing face validity. Missing values of predictors were
dealt with multiple imputation to avoid loss of useful in-
formation. Overfitting issues were reduced by a large
sample size and through optimism-adjustment methods.
We identified the components of the composite out-
come by a Delphi survey of experts, and prioritised for
their clinical importance, thereby ensuring that only the
clinically most relevant outcomes were included. An a
priori expert workshop provided guidance to minimise
bias from treatment paradox. We addressed this prob-
lem by including administration of anti-hypertensives
and magnesium sulfate as predictors, and delivery before
34 weeks as an outcome [17]. In women with severe
pre-eclampsia, magnesium sulfate is administered either
for prevention of eclamptic seizures, or more recently,
for neuroprotection of the preterm infant [37]. However,
we expect the proportion of women who received it
solely for fetal neuroprotection to be small, and less
likely to significantly alter the performance of the
models. We had sufficient sample size for the chosen
number of candidate predictors [12]. Our models, par-
ticularly PREP-L and also PREP-S by 48 hours, validated
well in external populations despite variations in coun-
try, setting and management. This suggests the models
are transportable and potentially useful for other non-
UK populations.
We only assessed predictors that are available in
current everyday practice in high-resource settings,
which may be seen as a weakness. Differences in man-
agement could affect the performance of the model. Al-
though the models included predictors of composite
outcome, we were unable to identify those associated
with specific outcomes due to the small numbers of in-
dividual complications. The logistic model does not
allow for predictions over time and therefore we also de-
veloped a survival model to provide risks at various time
points including at 48 hours. However, we censored at
34 weeks, as one of the components of the outcome was
delivery by 34 weeks. We were also unable to assess the
added predictive contribution of biomarkers (sFlt1, sEng,
PIGF) in maternal blood or urine, because the planned
ASTRONAUT study which was going to provide data on
biomarkers did not commence. We also could not differ-
entiate iatrogenic premature births from spontaneous
births. However, it is likely that pre-eclampsia and its
complications, such as abruption, could predispose to
spontaneous preterm labour [38]. Although admission to
neonatal intensive care unit was considered an indica-
tion of morbidity by Delphi consensus [13, 39], its inclu-
sion as a perinatal outcome may have weakened the
prediction of other more clinically relevant outcomes.
Due to the non-availability of all predictors in external
datasets, we were unable to validate the original PREP
models. However, our validation of reduced PREP-L and
PREP-S models gives an insight into how the original
models might perform. For example, a reduced PREP-L
model showed good discrimination and calibration for
predicting overall risk by discharge, and thus we expect
the original PREP-L to have similar, if not better, per-
formance when fully externally validated.
Comparison to existing evidence
Current prediction models, such as PIERS and mini
PIERS, included women with any onset pre-eclampsia,
and not specifically those with early onset pre-eclampsia
[4, 40]. Furthermore, existing models do not have suffi-
cient sample size for predicting complications at
48 hours in women with early onset pre-eclampsia. They
evaluated a large number of predictors for relatively
fewer outcomes observed at 48 hours, and used the
worst values of the tests, which may have overestimated
the performance of the model [12]. Effective interven-
tions such as delivery and anti-hypertensives could have
contributed to the observed absence of traditional risk
factors such as blood pressure, a crucial part of clini-
cian’s risk assessment, in these models [4, 40].
The performance of the PIERS model was dominated
by haematological complications, such as transfusion of
any blood product or low platelet count, which contrib-
uted to about half of all complications. Transfusion of
blood products scored the lowest for clinical importance
in the management of women with early-onset pre-
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eclampsia, in a survey of experts [41]. Our PREP models’
predictions were heavily influenced by risk of early deliv-
ery before 34 weeks, a clinically more important out-
come which helps inform mothers make informed
decisions. Compared to the current PIERS model that
had a C-statistic of between 0.7 and 0.8 at one week
after admission, the PREP-L model showed discrimin-
ation of over 0.8 for a longer period until postnatal dis-
charge from the hospital.
Relevance to clinical care
Currently, mothers diagnosed with early onset pre-
eclampsia in secondary care are transferred to tertiary
hospitals. However, with only a third of these mothers
suffering a complication by 48 hours, in current practice,
many mothers diagnosed with the condition in second-
ary care would have been transferred to a tertiary centre.
The promising discrimination and calibration perform-
ance of the PREP-S at 48 hours makes it suitable for use
as a triage tool, in accurately identifying mothers for in
utero transfer to tertiary care unit. It will also determine
use of corticosteroids depending on the predicted prob-
ability of complications. With good agreement between
the predicted and observed risk of complications in the
PREP-S at 48 hours in the low- and intermediate-risk
groups, women with a predicted probability of complica-
tions below 50% can avoid unnecessary transfer to ter-
tiary units. Women categorised to be low risk by the
PREP-L model could be followed-up in an outpatient
setting, with high- and very high-risk women monitored
as inpatients with regular intensive monitoring.
The model is available for everyday use in clinical
practice as an excel sheet, and is being developed as an
app to obtain individualised risk estimates for decisions
on further management. Provision of personalised risk
information allows parents to have the opportunity to
discuss the expected outcomes. It is important to recog-
nise that all prediction models in this field, including
our PREP models, provides risk estimates in the context
of current care and clinical management decisions. The
models are not designed to guide clinicians’ decisions on
choice of management such as timing of delivery, ad-
ministration of anti-hypertensives and magnesium sul-
fate. A woman with a low predicted risk should be
viewed as an individual with low outcome risk if current
care pathways are used, as it may be the clinical care
that results in her low-risk status.
Relevance to research
The next stage in this prediction research is evaluation
of the impact of using PREP models in clinical practice,
in terms of whether they help improve subsequent ma-
ternal and perinatal outcomes; this requires well-
planned robust randomised trials. The threshold for
intervention, such as transfer to a tertiary unit or admis-
sion to the hospital and subsequent delivery, needs to be
established by working with Patient and Public Involve-
ment groups. The design for such clinical trials should
be to randomise centres on use of PREP models as triag-
ing tools to plan management in women with early onset
pre-eclampsia. Evaluating the added value of biomarkers
to our models may also be a subject of future research,
though they have not been found useful in recent re-
search [42]. This may be supported by individual patient
data meta-analyses to improve power to identify import-
ant predictors.
Conclusion
The PREP models enable the individualised risk predic-
tion of complications in early-onset pre-eclampsia for
overall risk and by 48 hours. They use routinely col-
lected data and show promising performance upon in-
ternal and external validation. They can now be
considered for use to support healthcare professionals
and parents in making decisions on place of care, inten-
sity of monitoring, and early in utero tertiary transfer to
appropriate units.
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